Molecular nociceptive mechanisms in migraine: The migraine cascade.
CGRP
PACAP
animal model
experimental headache
human provocation model
migraine
migraine trigger
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
revised:
25
04
2024
received:
02
02
2024
accepted:
25
04
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
This review will explore the categorization of migraine-provoking molecules, their cellular actions, site of action and potential drug targets based on the migraine cascade model. Personal experience and literature. Migraine impacts over 1 billion people worldwide but is underfunded in research. Recent progress, particularly through the human and animal provocation model, has deepened our understanding of its mechanisms. This model have identified endogenous neuropeptides such as calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide (PACAP) that induces controlled migraine-like attacks leading to significant discoveries of their role in migraine. This knowledge led to the development of CGRP-inhibiting drugs; a groundbreaking migraine treatment now accessible globally. Also a PACAP-inhibiting drug was effective in a recent phase II trial. Notably, rodent studies have shed light on pain pathways and the mechanisms of various migraine-inducing substances identifying novel drug targets. This is primarily done by using selective inhibitors that target specific signaling pathways of the known migraine triggers leading to the hypothesized cellular cascade model of migraine. The model of migraine presents numerous opportunities for innovative drug development. The future of new migraine treatments is limited only by the investment from pharmaceutical companies.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16333Informations de copyright
© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137. doi:10.1186/S10194-020-01208-0
NIH Research Portfolio Online Reporting Tools (RePORT). Report on NIH funding vs. global burden of disease. https://report.nih.gov/report‐nih‐funding‐vs‐global‐burden‐disease
Sobocki P, Lekander I, Berwick S, Olesen J, Jönsson B. Resource allocation to brain research in Europe (RABRE). Eur J Neurosci. 2006;24:2691‐2693.
Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703‐711.
Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58:700‐714.
Ashina M, Hansen JM, Á Dunga BO, et al. Human models of migraine—short‐term pain for long‐term gain. Nat Rev Neurol. 2017;13:713‐724.
Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci. 1994;15:149‐153.
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54‐61.
H. Lundbeck A/S. Corporate release: Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention. https://mb.cision.com/Main/18215/3754245/1995698.pdf
Pellesi L, Al‐Karagholi MAM, Chaudhry BA, et al. Two‐hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia. 2020;40:1212‐1223.
Ghanizada H, Al‐Karagholi MAM, Arngrim N, et al. Effect of adrenomedullin on migraine‐like attacks in patients with migraine: a randomized crossover study. Neurology. 2021;96:e2488‐e2499.
Ghanizada H, Al‐Karagholi MAM, Walker CS, et al. Amylin analog pramlintide induces migraine‐like attacks in patients. Ann Neurol. 2021;89:1157‐1171.
Ghanizada H, Al‐Karagholi MAM, Arngrim N, et al. PACAP27 induces migraine‐like attacks in migraine patients. Cephalalgia. 2020;40:57‐67.
Brayden JE. Functional roles of KATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol. 2002;29:312‐316.
Quast U. ATP‐sensitive K+ channels in the kidney. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:213‐225.
Lückhoff A, Busse R. Activators of potassium channels enhance calcium influx into endothelial cells as a consequence of potassium currents. Naunyn Schmiedebergs Arch Pharmacol. 1990;342:94‐99.
Guo S, Olesen J, Ashina M. Phosphodiesterase 3 inhibitor cilostazol induces migraine‐like attacks via cyclic AMP increase. Brain. 2014;137:2951‐2959.
Al‐Karagholi MAM, Hansen JM, Guo S, et al. Opening of ATP‐sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain. 2019;142:2644‐2654.
Al‐Karagholi MAM, Ghanizada H, Waldorff Nielsen CA, et al. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain. 2021;162:2512‐2520.
Olesen J, Thomsen LL, Lassen LH, Olesen IJ. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia. 1995;15:94‐100.
Munro G, Jansen‐Olesen I, Olesen J. Animal models of pain and migraine in drug discovery. Drug Discov Today. 2017;22:1103‐1111.
Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. Lancet. 1997;349:401‐402.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338‐350.
Markovics A, Kormos V, Gaszner B, et al. Pituitary adenylate cyclase‐activating polypeptide plays a key role in nitroglycerol‐induced trigeminovascular activation in mice. Neurobiol Dis. 2012;45:633‐644.
Ernstsen C, Christensen SL, Olesen J, Kristensen DM. No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine. Cephalalgia. 2021;41:329‐339.
Pradhan AA, Smith ML, McGuire B, Tarash I, Evans CJ, Charles A. Characterization of a novel model of chronic migraine. Pain. 2014;155:269‐274.
Russo AF, Kuburas A, Kaiser EA, Raddant AC, Recober A. A potential preclinical migraine model: CGRP‐sensitized mice. Mol Cell Pharmacol. 2009;1:264‐270.
Christensen SL, Petersen S, Kristensen DM, Olesen J, Munro G. Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine‐like pain. Cephalalgia. 2019;39:1827‐1837.
Guo S, Ernstsen C, Hay‐Schmidt A, et al. PACAP signaling is not involved in GTN‐ and levcromakalim‐induced hypersensitivity in mouse models of migraine. J Headache Pain. 2022;23:155. doi:10.1186/S10194-022-01523-8
Kuburas A, Mason BN, Hing B, et al. PACAP induces light aversion in mice by an inheritable mechanism independent of CGRP. J Neurosci. 2021;41:4697‐4715.
Christensen SL, Petersen S, Sørensen DB, Olesen J, Jansen‐Olesen I. Cilostazol induces C‐fos expression in the trigeminal nucleus caudalis and behavioural changes suggestive of headache with the migraine‐like feature photophobia in female rats. Cephalalgia. 2018;38:452‐465.
Christensen SL, Munro G, Petersen S, et al. ATP sensitive potassium (KATP) channel inhibition: a promising new drug target for migraine. Cephalalgia. 2020;40:650‐664.
Bates EA, Nikai T, Brennan KC, et al. Sumatriptan alleviates nitroglycerin‐induced mechanical and thermal allodynia in mice. Cephalalgia. 2010;30:170‐178.
Capuano A, Greco MC, Navarra P, Tringali G. Correlation between algogenic effects of calcitonin‐gene‐related peptide (CGRP) and activation of trigeminal vascular system, in an in vivo experimental model of nitroglycerin‐induced sensitization. Eur J Pharmacol. 2014;740:97‐102.
Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF. Role of calcitonin gene‐related peptide in light‐aversive behavior: implications for migraine. J Neurosci. 2009;29:8798‐8804.
Christensen SL, Rasmussen RH, Ernstsen C, et al. CGRP‐dependent signalling pathways involved in mouse models of GTN‐ cilostazol‐ and levcromakalim‐induced migraine. Cephalalgia. 2021;41:1413‐1426.
Rea BJ, Wattiez A‐S, Waite JS, et al. Peripherally administered calcitonin gene‐related peptide induces spontaneous pain in mice: implications for migraine. Pain. 2018;159:2306‐2317.
Ernstsen C, Christensen SL, Rasmussen RH, et al. The PACAP pathway is independent of CGRP in mouse models of migraine. Brain. 2022;145:2450‐2460. In pres.
Thomsen LL, Kruuse C, Iversen HKOJ. A nitric oxide donor triggers genuine migraine attacks. Eur J Neurol. 1994;1:73‐80.
Guo S, Christensen AF, Liu ML, Janjooa BN, Olesen J, Ashina M. Calcitonin gene‐related peptide induced migraine attacks in patients with and without familial aggregation of migraine. Cephalalgia. 2017;37:114‐124.
Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine‐like attacks in patients with migraine without aura. Brain. 2009;132:16‐25.
Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 2003;126:241‐247.
Lund AM, Hannibal J. Localization of the neuropeptides pituitary adenylate cyclase‐activating polypeptide, vasoactive intestinal peptide, and their receptors in the basal brain blood vessels and trigeminal ganglion of the mouse CNS; an immunohistochemical study. Front Neuroanat. 2022;16:991403. doi:10.3389/FNANA.2022.991403
Olesen J. Personal view: modelling pain mechanisms of migraine without aura. Cephalalgia. 2022;42:1425‐1435.
Olesen J, Burstein R, Ashina M, Tfelt‐Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 2009;8:679‐690.
Winner PK, McAllister P, Chakhava G, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021;325:2348‐2356.
Khan S, Amin FM, Christensen CE, et al. Meningeal contribution to migraine pain: a magnetic resonance angiography study. Brain. 2019;142:93‐102.
Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A. 2004;101:4274‐4279.
Christensen SL, Ernstsen C, Olesen J, Kristensen DM. No central action of CGRP antagonising drugs in the GTN mouse model of migraine. Cephalalgia. 2020;40:924‐934.
Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med. 2015;7:308ra157.
Ashina M, Doležil D, Bonner JH, et al. A phase 2, randomized, double‐blind, placebo‐controlled trial of AMG 301, a pituitary adenylate cyclase‐activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia. 2021;41:33‐44.
Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport. 1993;4:1027‐1030.
Quayle JM, Nelson MT, Standen NB. ATP‐sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev. 1997;77:1165‐1232.
Della PA, Mikhailov N, Giniatullin R. The emerging role of mechanosensitive piezo channels in migraine pain. Int J Mol Sci. 2020;21:696. doi:10.3390/IJMS21030696
Gupta S, Bhatt DK, Boni LJ, Olesen J. Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia. 2010;30:27‐36.
Christensen SL, Rasmussen RH, La CS, et al. Smooth muscle ATP‐sensitive potassium channels mediate migraine‐relevant hypersensitivity in mouse models. Cephalalgia. 2022;42:93‐107.
Messlinger K, Balcziak LK, Russo AF. Cross‐talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators. J Neural Transm (Vienna). 2020;127:431‐444.
Shibata M, Suzuki N. Exploring the role of microglia in cortical spreading depression in neurological disease. J Cereb Blood Flow Metab. 2017;37:1182‐1191.
Theoharides TC, Donelan J, Kandere‐Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005;49:65‐76.
Bhatt DK, Gupta S, Olesen J, Jansen‐Olesen I. PACAP‐38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: possible involvement of mast cells. Cephalalgia. 2014;34:877‐886.
Baun M, Pedersen MHF, Olesen J, Jansen‐Olesen I. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP‐38. Cephalalgia. 2012;32:337‐345.
Ashina M. Migraine. N Engl J Med. 2020;383:1866‐1876.
Do TP, Deligianni C, Amirguliyev S, et al. Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans. Brain. 2023;146:5224‐5234.
Jahangir A, Terzic A. K(ATP) channel therapeutics at the bedside. J Mol Cell Cardiol. 2005;39:99‐112.
Gozalov A, Jansen‐Olesen I, Klaerke D, Olesen J. Role of KATP channels in cephalic vasodilatation induced by calcitonin gene‐related peptide, nitric oxide, and transcranial electrical stimulation in the rat. Headache. 2008;48:1202‐1213.
Ben Aissa M, Tipton AF, Bertels Z, et al. Soluble guanylyl cyclase is a critical regulator of migraine‐associated pain. Cephalalgia. 2018;38:1471‐1484.
Kruuse C, Khurana TS, Rybalkin SD, et al. Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. Eur J Pharmacol. 2005;521:105‐114.
Guo S, Goetze JP, Jeppesen JL, et al. Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers. Peptides. 2015;74:33‐42.
Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross‐talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007;100:1569‐1578.
Pardutz A, Schoenen J. NSAIDs in the acute treatment of migraine: a review of clinical and experimental data. Pharmaceuticals. 2010;3:1966‐1987.
Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H1‐receptor. Support for the NO hypothesis of migraine. Neuroreport. 1995;6:1475‐1479.